CDXC News and Press, ChromaDex Corporation From 11/09/23

ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor p...

2023-11-08 21:02:16 ET ChromaDex Corporation (CDXC) Q3 2023 Earnings Conference Call November 8, 2023, 04:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - CEO Brianna Gerber - CFO Conference Call Participants Ram Se...

2023-11-08 16:04:14 ET More on ChromaDex ChromaDex Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on ChromaDex Historical earnings data for ChromaDex Financial information for ChromaDex For further details see: ChromaDex GAAP EPS of ...

Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023. ChromaDex Corp. (NASDAQ: CDXC) today announced financial r...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Tru Niagen ® Pro 1,000mg is recommended by physicians and used by pro-athletes as it is clinically proven to boost NAD + levels by up to 150% in as little as three weeks ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleoti...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

ChromaDex Corporation (CDXC) is expected to report $-0.03 for Q3 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 8, 2023 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2023...

The global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex, and the #1 selling pet supplement brand in the USA*, Zesty Paws ® , debut cellular health supplement featuring ChromaDex’s industry leading healthy aging ingredient, Nia...